Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: UNIPROT:P61278 (somatostatin)
 22,083 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

Endocrine tumours constitute a homogeneous network of tumours scattered in the body and characterized by several common features including their capacity to secrete hormones, their association as part of inherited syndrome and their ability to be explored either by functioning imaging than by morphological imaging. However, they have a broad and initially misleading clinical spectrum. Staging of these tumours must be multidisciplinary with the association of primary tumour exploration, staging and follow-up. It also contribute to the screening of complications due to hormonal secretions, the exploration of inherited syndromes and a second cancer diagnosis. First we review the technical characteristics of each imaging modality including morphological imaging (computed tomography, magnetic resonance imaging), metabolic imaging (somatostatin receptors scintigraphy, PET-scan), endoscopy and vascular imaging. Then we review for each endocrine tumour localization and clinical presentation, the imaging strategy as well as the most common morphological and functional features.
 ...
PMID:[Imaging strategy for staging and follow-up of endocrine tumors]. 1718 74

Gastroenteropancreatic endocrine tumors (GEP ETs) constitute a spectrum of tumors that arise throughout the entire body but are drawn together under a common definition based on the expression of proteins derived from granules, vesicles, or both. GEP ET characterization is dependent on the primary tumor, and encompasses various factors: the WHO classification; hormone-related symptom recognition; hormone marker measurements; screening for inherited syndromes; staging; and somatostatin receptor characterization. Hypervascularization and somatostatin expression constitute major features of endocrine tumors that affect diagnosis, imaging, and therapy. GEP ET prognosis is characterized by its diversity, including a subgroup of patients with slowly progressive disease even at the metastatic stage. Prognosis assessment is mainly based on WHO classification and staging. A second cancer and cardiovascular comorbidity might also play a major prognostic part when present. Mastery of several key points analyzed in this Review, to be applied during the diagnostic and prognostic processes, is essential for defining a tailored therapeutic management.
 ...
PMID:Gastroenteropancreatic endocrine tumors: clinical characterization before therapy. 1731 31